Silver Book Fact

Investments in cancer care generated $598 billion of additional value for cancer patients diagnosed between 1983 and 1999.

Philipson, T, M Eber, D Lakdawalla, M Corral, R Conti, and D Goldman. An Analysis of Whether Higher Health Care Spending is ?Worth it? in the Case of Cancer. Health Affairs. 2012; 31(4): 667-75. http://content.healthaffairs.org/content/31/4/667.abstract

Reference

Title
An Analysis of Whether Higher Health Care Spending is ?Worth it? in the Case of Cancer
Publication
Health Affairs
Publication Date
2012
Authors
Philipson, T, M Eber, D Lakdawalla, M Corral, R Conti, and D Goldman
Volume & Issue
Volume 31, Issue 4
Pages
667-75
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.  
  • Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months…  
  • Surgical biopsy for lumps in the breast was found by one study to cost 2 1/2 to 3 times more than image-guided core-needle biopsy ($698 versus $243).  
  • Between 1990/1991 and 2008, the overall cancer mortality rates decreased by 22.9 percent in men and 15.3 percent in women—around 1,024,400 deaths avoided—primarily due to reductions in tobacco use among…  
  • Treating cancer patients with oral medicine versus intravenous chemotherapy results in a 2/3 reduction in hospital time and a greater than 50% reduction in costly medication side effects.